Treatment of bruxism, masseteric myalgia and hypertrophy with botulinum toxin type A
DOI:
https://doi.org/10.6016/ZdravVestn.3030Keywords:
bruxism, myalgia, masseteric hypertrophy, TMJ, botulinum toxinAbstract
Background: Bruxism (nocturnal dental clenching and grinding) is a persistent problem that affects many systems, and is difficult to treat. It causes pathological abrasions and dental injuries, as well as fractures of prosthodontic reconstructions, painful hypertrophy of masticatory muscles, and sometimes temporomandibular joint pains and headaches. Intramuscular botulinum toxin injections have been reported as a safe and effective means of treatment, causing reversible weakening of the masticatory muscles, which results in symptomatic relief.
Patients and methods: A retrospective analysis of the time period 2007 - 2018 was made, in which 72 patients with bruxism, masseteric myalgia and hypertrophy were treated with botulinum toxin injections.
Results: The majority of patients (58 of 64, i.e. 91%) reported symptomatic relief - pain diminished or subsided as did nocturnal bruxism, the masseters softened and lost volume. The effects of botulin toxin last 4 - 6 months, but in 29 (50%) patients, symptomatic relief was permanent and they did not return.
Conclusion: Treatment of bruxism, masseteric myalgia and hypertrophy with botullinum toxin injections is an effective and safe mode of treatment. Treatments can be repated, in case symptoms recur.
Downloads
References
1. Kwon KH, Shin KS, Yeon SH, Kwon DG. Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg. 2019;41(1):38.
DOI: 10.1186/s40902-019-0218-0
PMID: 31649901
2. Mor N, Tang C, Blitzer A. Temporomandibular myofacial pain treated with otbulinum toxin injection. Toxins (Basel). 2015;7(8):2791-800.
DOI: 10.3390/toxins7082791
PMID: 26213970
3. Al-Wayli H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J Clin Exp Dent. 2017;9(1):e112-7.
PMID: 28149474
4. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg. 1994;32(1):29-33.
DOI: 10.1016/0266-4356(94)90169-4
PMID: 8136335
5. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200.
DOI: 10.1054/bjps.2000.3526
PMID: 11254408
6. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000;38(5):466-71.
DOI: 10.1054/bjom.1999.0238
PMID: 11010775
7. Zhang LD, Liu Q, Zou DR, Yu LF. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX - A)for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg. 2016;54(7):736-40.
DOI: 10.1016/j.bjoms.2016.04.008
PMID: 27138229
8. Persaud R, Garas G, Sanjeev S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applicationa in non-cosmetic head and neck conditions. J R Soc Med Sh Rep. 2013;4(2):10.
DOI: 10.1177/2042533312472115
PMID: 23476731
9. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990;53(6):530.
DOI: 10.1136/jnnp.53.6.530
PMID: 2380736
10. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-70.
DOI: 10.1001/jama.285.8.1059
PMID: 11209178
11. Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg. 2012;65(10):1283-91.
DOI: 10.1016/j.bjps.2012.04.016
PMID: 22552262
12. Kostrzewa RM, Segura-Aguilar J. Botulinum neurotoxin: evolution from poison, to research tool—onto medicinal therapeutic and future pharmaceutical panacea. Neurotox Res. 2007;12(4):275-90.
DOI: 10.1007/BF03033911
PMID: 18201955
13. Prodnik L, Vesnaver A. Predstavitev kliničnega primera: zdravljenje Freyevega sindroma z botulin toksinom tip A. Zdrav Vestn. 2009;78(4):203-5.
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
